Financial Data and Key Metrics Changes - In the first quarter of 2025, the company reported revenue of $6.7 million, a 23% increase compared to $5.4 million in the same quarter of 2024 [22][6] - Gross margins improved to 85% in Q1 2025 from 84% in Q1 2024 [6][23] - GAAP net loss for Q1 2025 was $3.9 million, compared to a net loss of $3.5 million in Q1 2024 [24][26] - Cash and cash equivalents totaled approximately $8 million as of March 31, 2025, down from approximately $12.2 million at the end of 2024 [26] Business Line Data and Key Metrics Changes - Prescription gammaCore VA revenue grew 22% to $4.7 million in Q1 2025 from $3.9 million in Q1 2024 [7] - TRUVEGA net sales reached approximately $1.1 million, a 187% increase from the previous year [10] - Revenue from channels outside the United States increased to $513,000 in Q1 2025 from $449,000 in the same period last year [14] Market Data and Key Metrics Changes - The VA Hospital Administration estimates around 600,000 patients are treated for headaches in the VA system, with a significant number of fibromyalgia patients also identified [8][9] - The company has dispensed gammaCore devices to approximately 9,500 veterans, representing about 1.6% of the total addressable headache market within the VA system [9] Company Strategy and Development Direction - The company is transforming into a broader bioelectronic technology firm, focusing on medical devices and wellness products, with the acquisition of the Quell product line from Neurometrics being a key component [4][5] - The company aims to leverage established distribution channels, particularly in the VA hospital system, to accelerate the adoption of new products like Quell and Sparrow [20][32] - Plans to launch TRUVEGA in the UK and Canada later in 2025 are underway [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to sequential growth in core prescription channels and highlighted the positive momentum in both VA and direct-to-consumer channels [27][28] - The company anticipates that operating metrics will improve as revenues grow and one-time expenses decrease [28][33] - Management expects to achieve cash neutrality with quarterly revenue of about $9 million by the end of 2025 or early 2026 [16] Other Important Information - The company incurred additional one-time expenses for severance related to internal restructuring and the acquisition of Neurometrics [15] - The contribution margin of incremental revenue is approximately 65% with the current product mix [16] Q&A Session Summary Question: What are the expected margins for Quell by the end of the year? - Management indicated that while precise estimates are not available yet, they are optimistic that margins will be well above 60% once manufacturing is restarted [38][39] Question: How does cash look after the Neurometrics acquisition? - Cash levels are expected to remain similar to those reported as of March 31, with the acquisition costs primarily covered by cash on Neurometrics' balance sheet [43] Question: What is the growth outlook for top-line revenues? - Management expects mid to high single-digit sequential growth in the VA channel, potentially accelerating into the teens as new products are introduced [48] Question: How is the company expanding its sales efforts in the VA hospital system? - The company is adding headcount to its sales function to increase support in the VA hospital system, with a focus on new products [50][52] Question: What are the early results from selling TRUVEGA on Amazon? - Initial sales through Amazon have been promising, with a few hundred units sold, and the company is optimistic about future growth [56][57]

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) The company's financial information details its balance sheet, income statement, cash flows, and related notes [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The company reported total assets of **$16.0 million** as of March 31, 2025, with net sales growing to **$6.7 million** [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to **$16.0 million** as of March 31, 2025, primarily due to a reduction in marketable securities Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $3,777 | $3,450 | | Marketable securities | $3,982 | $8,519 | | Total current assets | $11,972 | $16,300 | | **Total assets** | **$16,041** | **$20,471** | | **Liabilities & Equity** | | | | Total current liabilities | $7,856 | $9,152 | | **Total liabilities** | **$11,676** | **$12,927** | | **Total stockholders' equity** | **$4,365** | **$7,544** | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Net sales increased by **23.4%** to **$6.7 million** in Q1 2025, but the net loss widened to **$3.9 million** Q1 2025 vs Q1 2024 Statement of Operations (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net sales | $6,719 | $5,443 | | Gross profit | $5,706 | $4,555 | | Total operating expenses | $9,528 | $8,404 | | Loss from operations | $(3,822) | $(3,849) | | **Net loss** | **$(3,855)** | **$(3,506)** | | Net loss per share | $(0.47) | $(0.53) | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities significantly increased to **$4.4 million** in Q1 2025, with cash, cash equivalents, and restricted cash ending at **$4.0 million** Cash Flow Summary for the Three Months Ended March 31 (in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(4,355) | $(2,558) | | Net cash provided by (used in) investing activities | $4,500 | $0 | | Net cash provided by financing activities | $180 | $0 | | **Net (de)increase in cash** | **$327** | **$(2,482)** | | Cash, cash equivalents, and restricted cash – end of period | $4,027 | $8,099 | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Key notes highlight liquidity challenges, revenue concentration with the VA, and the acquisition of NeuroMetrix, Inc - The company has a history of significant net losses and negative cash flow from operations, funding its activities primarily through the sale of securities[37](index=37&type=chunk)[38](index=38&type=chunk) Management believes its current cash position and expected cash flow will be sufficient for at least the next 12 months[41](index=41&type=chunk) - Revenue is heavily concentrated, with sales to the U.S. Department of Veterans Affairs (VA) and Department of Defense accounting for **70.3%** of net sales in Q1 2025 and **71.2%** in Q1 2024[42](index=42&type=chunk) Net Sales Disaggregation for Q1 (in thousands) | Channel/Market | 2025 | 2024 | | :--- | :--- | :--- | | **By Channel** | | | | Rx gammaCore – VA | $4,721 | $3,875 | | Truvaga | $1,106 | $385 | | **By Geography** | | | | United States | $6,206 | $4,994 | | United Kingdom | $451 | $385 | | **Total Net Sales** | **$6,719** | **$5,443** | - On May 1, 2025, the company completed its acquisition of NeuroMetrix, Inc. (NURO), which will now operate as a wholly-owned subsidiary[76](index=76&type=chunk)[77](index=77&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes **23%** year-over-year revenue growth to increased sales of Rx gammaCore and Truvaga, while managing liquidity challenges [Overview](index=25&type=section&id=Overview) electroCore focuses on non-invasive vagus nerve stimulation (nVNS) technology, with key products gammaCore and Truvaga, and recently acquired NeuroMetrix - The company's business is centered on its proprietary non-invasive vagus nerve stimulation (nVNS) technology[91](index=91&type=chunk) - Key product categories include: - **gammaCore:** A prescription device for primary headache conditions - **Truvaga:** A direct-to-consumer general wellness product - **TAC-STIM:** A human performance product developed with the U.S. Department of Defense[93](index=93&type=chunk)[94](index=94&type=chunk)[95](index=95&type=chunk)[96](index=96&type=chunk) - The two largest customers are the U.S. VA (**70.3%** of revenue in Q1 2025) and the UK NHS (**5.3%** of revenue in Q1 2025)[99](index=99&type=chunk)[100](index=100&type=chunk)[103](index=103&type=chunk) - The company acquired NeuroMetrix, Inc. (NURO) on May 1, 2025, to add the Quell® platform for fibromyalgia and chronic pain to its portfolio[105](index=105&type=chunk) [Results of Operations](index=29&type=section&id=Results%20of%20Operations) Net sales increased by **$1.3 million (23%)** in Q1 2025, driven by higher Rx gammaCore and Truvaga sales, with gross margin stable at **85%** - Net sales for Q1 2025 increased **23%** YoY, primarily due to a **$0.8 million** increase in Rx gammaCore sales to the VA and a **$0.7 million** increase in Truvaga sales[114](index=114&type=chunk)[115](index=115&type=chunk) - Gross margin remained strong and consistent at **85%** in Q1 2025, compared to **84%** in Q1 2024, reflecting favorable product mix and increased sales[116](index=116&type=chunk) - Selling, general and administrative (SG&A) expenses increased by **11%** YoY to **$8.9 million**, driven by targeted investments in sales and marketing to support commercial efforts[118](index=118&type=chunk) [Liquidity and Capital Resources](index=30&type=section&id=Liquidity%20and%20Capital%20Resources) The company relies on securities sales and an ATM facility for funding, holding **$8.0 million** in cash and marketable securities as of March 31, 2025 - The company's cash, cash equivalents, restricted cash, and marketable securities totaled **$8.0 million** as of March 31, 2025[126](index=126&type=chunk) - The company relies on an At-The-Market (ATM) facility to sell common stock for funding During Q1 2025, it raised approximately **$0.2 million** in net proceeds from this facility[127](index=127&type=chunk) - Management believes its current cash position and expected cash flow from operations will be sufficient to fund operating expenses and capital requirements for at least the next 12 months from the issuance date of the financial statements[129](index=129&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=32&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces foreign currency and interest rate risks but does not currently use hedging instruments - The company has foreign currency exchange risk related to sales denominated in British Pound Sterling and license revenue in Japanese Yen[130](index=130&type=chunk) - Interest rate risk is limited to the company's portfolio of cash, cash equivalents, and short-term marketable securities, and is considered minimal[132](index=132&type=chunk) - The company does not currently hedge its foreign currency or interest rate exposure[132](index=132&type=chunk) [Item 4. Controls and Procedures](index=32&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal control over financial reporting - Based on an evaluation as of March 31, 2025, the CEO and CFO concluded that the company's disclosure controls and procedures were effective[135](index=135&type=chunk) - No changes occurred during the quarter ended March 31, 2025, that materially affected or are reasonably likely to materially affect the company's internal control over financial reporting[136](index=136&type=chunk) [PART II. OTHER INFORMATION](index=33&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section covers legal proceedings, risk factors, equity sales, other information, and exhibits [Item 1. Legal Proceedings](index=33&type=section&id=Item%201.%20Legal%20Proceedings) The company states that it is not currently a party to any legal proceedings that would have a material adverse effect on its financial condition or results of operations - The company believes there are no current legal proceedings or claims pending that would have a material adverse effect on its financial condition or operations This information is incorporated by reference from Note 14 of the financial statements[70](index=70&type=chunk)[138](index=138&type=chunk) [Item 1A. Risk Factors](index=33&type=section&id=Item%201A.%20Risk%20Factors) This section directs investors to the risk factors previously disclosed in the company's Annual Report on Form 10-K - The company refers readers to the risk factors detailed in its Annual Report on Form 10-K for the year ended December 31, 2024[139](index=139&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=33&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - None[140](index=140&type=chunk) [Item 5. Other Information](index=33&type=section&id=Item%205.%20Other%20Information) The company disclosed that no director or Section 16 officer adopted or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the quarter - No director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangements during the first quarter of 2025[145](index=145&type=chunk) [Item 6. Exhibits](index=34&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including officer certifications and Inline XBRL data files - The report includes a list of filed exhibits, primarily consisting of CEO and CFO certifications as required by the Sarbanes-Oxley Act and XBRL data files[147](index=147&type=chunk)

[Q1 2025 Financial Results and Business Update](index=1&type=section&id=electroCore%20Announces%20First%20Quarter%202025%20Financial%20Results) electroCore reports strong Q1 2025 revenue growth, improved operational metrics, and strategic NeuroMetrix acquisition [Recent Highlights and Management Commentary](index=1&type=section&id=Recent%20Highlights) Q1 2025 revenue increased 23% to $6.7 million, driven by strategic acquisition and improved operational efficiency - Closed the acquisition of NeuroMetrix, Inc., which contributed approximately **$170,000** in unaudited Quell net sales in Q1 2025[1](index=1&type=chunk) - Management noted that increased G&A expenses of **$665,000** were due to seasonal factors, severance, and one-time costs from the NeuroMetrix transaction[2](index=2&type=chunk) - The CEO stated that the NeuroMetrix acquisition positions the company as a significant player in non-invasive bioelectronic technology with a more diversified product line[2](index=2&type=chunk) [Q1 2025 Financial Performance](index=1&type=section&id=First%20Quarter%202025%20Financial%20Results%20and%20Select%20Guidance) Q1 2025 net sales grew 23% to $6.7 million, with stable gross margins but increased operating expenses leading to a net loss Q1 2025 Revenue by Channel (in thousands) | Channel | 2025 | 2024 | % Change | | :--- | :--- | :--- | :--- | | Rx gammaCore™ – VA | $4,721 | $3,875 | 22% | | Rx gammaCore – U.S. Commercial | $289 | $433 | -33% | | Outside the United States | $513 | $449 | 14% | | Truvaga™ | $1,106 | $385 | 187% | | **Total Before TAC-STIM™** | **$6,629** | **$5,142** | **29%** | | TAC-STIM | $90 | $301 | -70% | | **Total Revenue** | **$6,719** | **$5,443** | **23%** | - Gross profit increased to **$5.7 million** with a gross margin of **85%**, compared to **$4.6 million** and **84%** margin in Q1 2024[6](index=6&type=chunk) - Total operating expenses rose to **$9.5 million** from **$8.4 million** in Q1 2024, mainly due to increased investment in selling and marketing and higher R&D headcount[6](index=6&type=chunk)[7](index=7&type=chunk)[8](index=8&type=chunk) Q1 2025 Profitability Summary | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | GAAP Net Loss | $(3.9) million | $(3.5) million | | GAAP Loss Per Share | $(0.47) | $(0.53) | | Adjusted EBITDA Net Loss | $(3.1) million | $(3.2) million | - Cash, cash equivalents, restricted cash, and marketable securities totaled approximately **$8.0 million** at March 31, 2025, down from **$12.2 million** at December 31, 2024[12](index=12&type=chunk) [Full Year 2025 Outlook](index=2&type=section&id=Full%20Year%202025%20Outlook) Company projects full-year 2025 revenue of $30.0 million and anticipates meaningful contribution from NeuroMetrix acquisition - Expects full-year 2025 total revenue to be approximately **$30.0 million**[13](index=13&type=chunk) - Projects net cash used for the next three quarters to be between **$3.8 million** and **$4.3 million**[13](index=13&type=chunk) - Anticipates that NeuroMetrix will provide meaningful revenue by the year ending December 2025[13](index=13&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) Detailed financial statements for Q1 2025 show operational results, balance sheet position, and non-GAAP reconciliations [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2025 statement shows $6.7 million net sales, $5.7 million gross profit, and a GAAP net loss of $3.9 million Q1 2025 Statement of Operations (in thousands, except per share data) | | Three months ended March 31, | | :--- | :--- | :--- | | | **2025** | **2024** | | Net sales | $6,719 | $5,443 | | Gross profit | $5,706 | $4,555 | | Total operating expenses | $9,528 | $8,404 | | Loss from operations | $(3,822) | $(3,849) | | Net loss | $(3,855) | $(3,506) | | Net loss per share - Basic and Diluted | $(0.47) | $(0.53) | [Condensed Consolidated Balance Sheet Information](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheet%20Information) As of March 31, 2025, total assets were $16.0 million, total liabilities $11.7 million, and total equity $4.4 million Balance Sheet Highlights (in thousands) | | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $3,777 | $3,450 | | Total assets | $16,041 | $20,471 | | Total liabilities | $11,676 | $12,927 | | Total equity | $4,365 | $7,544 | [Reconciliation of GAAP to Non-GAAP Measures](index=7&type=section&id=(Unaudited)%20Use%20of%20Non-GAAP%20Financial%20Measure) Reconciliation adjusts Q1 2025 GAAP net loss of $3.9 million to an Adjusted EBITDA net loss of $3.1 million Reconciliation of GAAP Net Loss to Adjusted EBITDA Net Loss (in thousands) | | Three months ended March 31, | | :--- | :--- | :--- | | | **2025** | **2024** | | **GAAP net loss** | **$(3,855)** | **$(3,506)** | | Depreciation and amortization | $155 | $206 | | Stock-based compensation | $540 | $484 | | Severance and other related charges | $180 | - | | Non-recurring one-time charges | $145 | - | | Other adjustments | $(171) | $(347) | | **Adjusted EBITDA net loss** | **$(3,054)** | **$(3,163)** | - The company uses Adjusted EBITDA as a non-GAAP measure to provide a useful indicator of its core operating performance, excluding non-cash charges and certain unpredictable expenses[23](index=23&type=chunk)[24](index=24&type=chunk) [Supplemental Information](index=3&type=section&id=Supplemental%20Information) Provides details on the Q1 2025 earnings call and standard forward-looking statement disclosures [Conference Call Information](index=3&type=section&id=Webcast%20and%20Conference%20Call%20Information) Management hosted a conference call on May 7, 2025, to discuss Q1 2025 financial results - A conference call to discuss Q1 2025 results was scheduled for May 7, 2025, at **4:30 PM EDT**[14](index=14&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) Standard safe harbor statement cautions on forward-looking statements and directs to SEC filings for risk factors - The report contains forward-looking statements concerning business prospects, clinical development, revenue guidance, and the impact of the NeuroMetrix acquisition[17](index=17&type=chunk) - Investors are advised that actual results could differ from projections and are directed to the risk factor disclosures in the company's SEC filings[17](index=17&type=chunk)

Core Insights - electroCore, Inc. reported first quarter 2025 net sales of $6.7 million, a 23% increase compared to $5.4 million in the same period of 2024 [3][6] - The company closed the acquisition of NeuroMetrix, which is expected to enhance its position in the non-invasive bioelectronic technology market [2][6] - The CEO highlighted a 29% growth in total revenue excluding TAC-STIM, indicating strong performance in core product lines [2][6] Financial Performance - Gross profit for the first quarter of 2025 was $5.7 million, representing an 85% gross margin, compared to $4.6 million and 84% gross margin in the first quarter of 2024 [4][18] - Total operating expenses increased to approximately $9.5 million from $8.4 million in the first quarter of 2024, driven by higher selling, general, and administrative expenses [5][6] - The GAAP net loss for the first quarter of 2025 was $3.9 million, or a loss of $0.47 per share, compared to a net loss of $3.5 million, or a loss of $0.53 per share, in the first quarter of 2024 [8][18] Revenue Breakdown - Sales of prescription gammaCore to the U.S. Department of Veterans Affairs (VA) reached $4.7 million, a 22% increase from $3.9 million in the prior year [4] - International sales grew by 14%, with total sales outside the United States amounting to $513,000 [4] - Truvaga wellness products saw significant growth, with sales increasing by 187% to $1.1 million compared to $385,000 in the first quarter of 2024 [4] Guidance and Outlook - For the full year 2025, the company expects total revenue to be approximately $30 million, with net cash used for the next three quarters projected between $3.8 million and $4.3 million [12] - The acquisition of NeuroMetrix is anticipated to contribute meaningful revenue by the end of 2025, expanding the company's product offerings [12]

Core Insights - The merger between electroCore, Inc. and NeuroMetrix, Inc. has been completed, enhancing electroCore's position in the bioelectronic technology market focused on non-invasive health solutions [1][3] - The acquisition of NeuroMetrix's Quell® Fibromyalgia Solution expands electroCore's portfolio and is expected to significantly increase its addressable market for chronic pain and wellness treatments [2][3] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company dedicated to improving health and quality of life through innovative non-invasive technologies [5] - Following the merger, NeuroMetrix will become an indirect wholly-owned subsidiary of electroCore, with its shares being de-listed from the Nasdaq Capital Market [3][7] Market Position and Strategy - The merger allows electroCore to leverage established distribution channels, particularly within the VA Hospital System, to accelerate the adoption of the Quell Fibromyalgia solution [3] - The addition of the Quell solution diversifies electroCore's offerings in non-pharmaceutical, non-invasive nerve stimulation, reinforcing its leadership in the bioelectronic technology sector [3]

Core Insights - electroCore, Inc. announced that its flagship wellness product, Truvaga Plus, is now compatible with the Apple Health app, enhancing user experience and health management [1][2] - Truvaga Plus is a hand-held vagus nerve stimulator aimed at providing stress relief, improving sleep, enhancing peace of mind, and improving focus [1] - The integration with the Apple Health app allows users to track their health data, including their progress with Truvaga Plus, in a consolidated view [2] Product Features - Truvaga Plus enables users to log their feelings after each session, utilizing the State of Mind API to monitor mental wellbeing over time [2] - The Apple Health app provides a secure platform for users to store and access important health information, leveraging the privacy features of iPhones [3] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through innovative non-invasive technologies [4]

Core Insights - electroCore, Inc. will report its financial results for Q1 2025 on May 7, 2025, after market close [1] - A webinar will be held at 4:30 PM EST on the same day to discuss the financial results and address investor questions [1] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on enhancing health and quality of life through innovative non-invasive technologies [2]

Core Insights - electroCore, Inc. announced new data at the 2025 International Brain Injury Association World Congress, highlighting the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI) [1][3] Study Findings - A study involving 102 patients with mild TBI showed that adjunctive use of gammaCore (nVNS) significantly improved 22 out of 27 measured concussive symptoms, with notable improvements in post-traumatic headache, nausea, dizziness, and depression [3] - The study indicated no significant difference in symptom improvement between patients with recent traumatic brain injuries (three months or less) and those with older injuries (three years or more), suggesting the potential benefits of neuromodulation regardless of the time since injury [3] Expert Commentary - Dr. Michael Ament emphasized the urgent need for nonpharmaceutical treatment options for mild TBI, reinforcing the role of vagus nerve stimulation in alleviating long-term effects [2][4] - Dr. Peter Staats, Chief Medical Officer of electroCore, praised Dr. Ament's research for demonstrating the clinical efficacy of gammaCore in improving concussive symptoms in a large patient cohort [4] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company focused on improving health through its nVNS technology platform, aiming to commercialize medical devices for managing and treating specific medical conditions [5]

Dan Goldberger, CEO, will host a group presentation on Wednesday, April 23, 2025 at 1:30 p.m. PT and host one-on-one meetings throughout both days. To schedule a one-on-one meeting with Mr. Goldberger, investors are encouraged to reach out to Planet MicroCap or electroCore's investor relations at ecor@fnkir.com. About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation ("nVNS") te ...

ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one of “The Americas’ Fastest Growing Companies 2025.” Debuting at number 125, electroCore joins 300 other companies dominating in their respective sectors. This is the sixth annual list that the Financial Times published, ranking companies based on the highest compound annual revenue growth between the years 2020 a ...